🔎 Trials Near Me

Home › COPD › South Carolina

Pag-aaral pangklinika para sa COPD sa South Carolina

14 pag-aaral para sa COPD ang naghahanap ng mga kalahok sa mga site sa South Carolina.

Mga Lungsod sa South Carolina

Opisyal na teksto ng pag-aaral (English)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  • Research Site, Anderson
  • Research Site, Charleston
  • Research Site, Gaffney
  • at 2 pa
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06283966

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

  • Clinical Research of Rock Hill, Rock Hill
Nagre-recruitPhase 2
Edad 40 hanggang 85 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07684820

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • AnMed Oglesby Center- Site Number : 8400074, Anderson
  • MD First Research - Lancaster- Site Number : 8400102, Lancaster
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07190209

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  • Research Site, Lancaster
  • Research Site, Spartanburg
Nagre-recruitPhase 2
Edad 40 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07082738

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • Research Site, Anderson
  • Research Site, Columbia
  • Research Site, Gaffney
  • at 2 pa
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  • Research Site, Rock Hill
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06883305

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Bogan Sleep Consultants, LLC, Columbia
  • Velocity Clinical Research, Gaffney, Gaffney
  • Clinical Research of Rock Hill, Rock Hill
  • at 1 pa
Nagre-recruitPhase 2/3
Edad 35 hanggang 80 · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07363694

STRIVE Post-Market Registry Study

  • AnMed Health, Anderson
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  • GSK Investigational Site, Greenville
  • GSK Investigational Site, Rock Hill
Nagre-recruitPhase 3
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07177339

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  • GSK Investigational Site, Spartanburg
  • GSK Investigational Site, Union
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06961214

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

  • GSK Investigational Site, Rock Hill
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Okt 8, 2025 · NCT06959095

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • Medical University of South Carolina (MUSC), Charleston
  • McLeod Health, Florence
Nagre-recruitObservasyonal na pag-aaral
Edad 50 pataas · Lahat ng kasarian · Na-update Ago 5, 2025 · NCT06122077

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.